Waeber B, de la Sierra A, Ruilope LM
The ADVANCE Trial: Clarifying the Role of Perindopril/Indapamide Fixed-Dose Combination in the Reduction of Cardiovascular and Renal Events in Patients with Diabetes Mellitus. [Journal Article]
Am J Cardiovasc Drugs 2009; 9(5):283-91.
Patients with type 2 diabetes mellitus exhibit a marked increase in cardiovascular and renal risk. A number of interventional trials have shown that these patients benefit greatly from aggressive BP lowering, especially when the drug regimen comprises an inhibitor of the renin-angiotensin system. The results of the placebo-controlled ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN MR Controlled Evaluation) trial, conducted in patients with type 2 diabetes, are exemplary in this respect. The systematic use of a fixed-dose combination containing the ACE inhibitor perindopril and the diuretic indapamide afforded substantial protection against cardiovascular mortality and myocardial infarction, while providing important renoprotection, reducing the development of micro- and macroalbuminuria, and allowing regression of nephropathy. The beneficial effects were obtained regardless of baseline BP and whether or not the patients were receiving antihypertensive therapy.
More from this journal |
